Lenvatinib-d4 is a deuterated form of Lenvatinib, which is an orally active, multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and rearranged during transfection (RET), demonstrating potent anticancer activity.